Search

Displaying results 1071 - 1080 of 5383 in total
  1. Drug

    Camphor

    go.drugbank.com/drugs/DB01744
    ApprovedInvestigationalWithdrawn

    Camphor is a bicyclic monoterpene ketone found widely in plants, especially Cinnamomum camphora. It is used topically as a skin antipruritic and as an anti-infective agent. When ingested, camphor has a rapid onset of toxic effects, and c...

    Mixtures: CHAP ICE (R) MEDICATED, Zam-Buk Ointment
  2. Drug

    Dengue virus serotype 4

    go.drugbank.com/drugs/DB22667
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  3. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

  4. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.

  5. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of

  6. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH

  7. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    L63930] Reduced gadolinium exposure is important for patients requiring repeated lifetime imaging - e.g. for multiple sclerosis, spinal conditions, or cancer surveillance - given clinical guidance to use … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  8. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

  9. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  10. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.